Article info
PDFShort Report
High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome
- ↵a Shien.chow{at}christie.nhs.uk
- ↵b victoriagalvisz{at}gmail.com
- ↵c manon.pillai{at}christie.nhs.uk
- ↵d Rebecca.leach{at}christie.nhs.uk
- ↵e elizabeth.keene{at}christie.nhs.uk
- ↵f andrea.spencer-shaw{at}christie.nhs.uk
- ↵g alaaeldin.shablak{at}uhs.nhs.uk
- ↵h Jonathan.shanks{at}christie.nhs.uk
- ↵i Tom.liptrot{at}christie.nhs.uk
- ↵j fiona.thistlethwaithe{at}christie.nhs.uk
- ↵k Robert.hawkins{at}christie.nhs.uk
Citation
High-dose interleukin2 – a 10-year single-site experience in the treatment of metastatic renal cell carcinoma: careful selection of patients gives an excellent outcome
Publication history
- Received June 10, 2016
- Accepted October 7, 2016
- First published October 18, 2016.
Online issue publication
February 15, 2021
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© The Author(s). 2016
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.